On October 5, 2021 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that management will host a virtual event on October 12, 2021 at 4:30 p.m. ET to highlight clinical data from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies (Press release, CRISPR Therapeutics, OCT 5, 2021, View Source [SID1234590883]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call and Webcast
To access the conference call, please dial +1 (866) 952-8559 (domestic) or +1 (785) 424-1743 (international) and reference the conference ID "CRISPR."

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A webcast replay will be available on the CRISPR Therapeutics website after the event and will be archived for 14 days.

About CTX110
CTX110, a wholly owned program of CRISPR Therapeutics, is a healthy donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 19, or CD19. CTX110 is being investigated in the ongoing CARBON trial.

About CARBON
The ongoing Phase 1 single-arm, multi-center, open label clinical trial, CARBON, is designed to assess the safety and efficacy of several dose levels of CTX110 for the treatment of relapsed or refractory B-cell malignancies.

On October 5, 2021 Scopus BioPharma Inc. (Nasdaq: "SCPS"), a clinical-stage biopharmaceutical company developing transformational therapeutics for serious diseases with significant unmet medical need, reported it will be presenting at the LD Micro Main Event, which is being held in-person and virtually from October 12th through 14th, 2021 (Press release, Scopus BioPharma, OCT 5, 2021, View Source [SID1234590807]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present on the recent launch of Duet Therapeutics, its wholly-owned subsidiary focused on immuno-oncology, which Scopus announced in September 2021.

Alan Horsager, Ph.D., President — Immuno-Oncology of Scopus and President and Chief Executive Officer of Duet, will be presenting in-person on behalf of the company. Dr. Horsager’s presentation will be part of Track 4 on Tuesday, October 12, 2021 at 11:00 AM Eastern Time / 8:00 AM Pacific Time at the Luxe Sunset Bel-Air in Los Angeles. The presentation will also be available for viewing on-demand on the LD Micro conference website. Management will be available for one-on-one meetings to be held throughout the conference.

Investors interested in attending the conference in-person or virtually can register here. Once registered, you can request one-on-one meetings with the company through the conference website.

Dr. Horsager recently presented at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society during which he discussed data from two different studies that suggest that DUET-01 and DUET-02, two of Duet’s unique bifunctional oligonucleotides, can expand the reach and efficacy of cancer immunotherapies beyond certain standard-of-care treatments.

As previously announced, Scopus will also be presenting at The MicroCap Rodeo’s Fall Harvest Best Ideas Conference on Wednesday, October 6, 2021 at 5:00 PM Eastern Time. Investors interested in attending the virtual conference can register here.

About LD Micro Main Event

The 2021 LD Micro Main Event (XIV) will be held at the Luxe Sunset Bel-Air in Los Angeles from October 12th through 14th, 2021. The festivities run from 8:00 AM Pacific Time through 5:30 PM Pacific Time on October 12th and 13th with a morning session on October 14th. This three-day, investor conference is expected to feature around 150 companies, presenting for 25 minutes each, as well as several influential keynotes in-person. For more information, please contact [email protected].

About the Duet Platform

Duet Therapeutics integrates the immunotherapy assets of Scopus and Olimmune, creating the Duet Platform. Olimmune was acquired by Scopus in June 2021. Duet is a wholly-owned subsidiary of Scopus.

The Duet Platform is comprised of three distinctive, complementary CpG-STAT3 inhibitors:

– RNA silencing CpG-STAT3siRNA ("DUET-01")
– Antisense CpG-STAT3ASO ("DUET-02")
– DNA-binding inhibitor CpG-STAT3decoy ("DUET-03")
DUET-01 is in a Phase 1 clinical trial, as a monotherapy, for B-cell non-Hodgkin lymphoma. Duet expects to file two INDs for DUET-02 in Q4 2022 in genitourinary and head & neck cancers, with clinical Phase 1 trials beginning in Q1 2023 in the United States. Duet is also evaluating combination therapies with checkpoint inhibitors.

On October 5, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, reported a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb(Press release, T-Cure Bioscience, OCT 5, 2021, View Source [SID1234590827]). These will be used to develop a diagnostic test to identify tumors that express KK-LC-1. Patients with KK-LC-1 positive tumors may be eligible inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Atlas Antibodies AB will provide all manufacturing and product supply for KK-LC-1 mAb for the companion diagnostic for clinical development. T-Cure is developing TCR-T therapeutics targeting Kita-Kyushu Lung Cancer Antigen 1 (KK-LC-1) for gastric, triple negative breast cancer, cervical, lung and other KK-LC-1 positive cancers.

T-Cure plans to develop the companion diagnostic assay to identify KK-LC-1 positive cancer patients for inclusion in the company sponsor clinical trial planned for 2022.

"We are excited that Atlas Antibodies will supply high quality mAb shown to have superior specificity in recognizing KK-LC-1 in the patients’ samples." stated Gang Zeng, Ph.D., Chief Executive Officer at T-Cure Bioscience. "Developing an immnunohistochemistry (IHC) diagnostic tool is key to identify the right patient population to be treated by our KK-LC-1 specific TCR-T."

We are delighted to start this collaboration with T-Cure Bioscience. It reflects one of our new business models of deploying our highly validated monoclonals through contract manufacturing in which both parties are enabled to focus on their core competencies," stated Nille Klæbel, Chief Executive Officer at Atlas Antibodies. "We are convinced that this creates a win-win situation for both parties.

On October 5, 2021 Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, based on its patented biophotonic technology, reported that its Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI), had received ethics board approval and placed LuViva devices at two of the three participating hospitals for clinical trials aimed at achieving Chinese FDA approval (Press release, Guided Therapeutics, OCT 5, 2021, View Source [SID1234590850]). The clinical study is expected to start next month, include approximately 400 patients and be completed this year or early next year. Participating hospitals include Fudan University Hospital, Qilu Hospital of Shandong University and Peking University People’s Hospital. The physicians testing LuViva at these institutions represent the leadership of the Chinese obstetrics and gynecology community and include Professor Dr. Wei Lihui of Peking University and Dr. Kong Beihua of Qilu Hospital. Dr. Wei is former National Chairwoman of the Chinese Society of Obstetrics and Gynecology and Dr. Kong is currently the vice chairman of the Chinese Society of Obstetrics and Gynecology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SMI also placed orders for additional LuViva devices and paid $100,000 to GTHP as part of an existing purchase order that totals $530,000, $252,000 of which has been paid thus far in 2021. The remaining $278,000 is due over the next five months. GTHP holds another purchase order from SMI for $2.5 million, $620,000 due upon SMI filing the clinical study results with Chinese FDA and $1,880,000 due upon approval by Chinese FDA. A recently signed distribution agreement then calls for minimum orders of $72 Million over the first four years post Chinese FDA approval.

"We are delighted that SMI has been able to recruit influential thought leaders to work with our products", said Gene Cartwright, CEO of Guided Therapeutics. "These recent developments auger well for the commercial viability of LuViva in China, the world’s most populous nation and second fastest growing medical device market".

According to the World Health Organization, cervical cancer is one of the most frequent cancers in women in the world and in China it is the second most common cancer among women. China has a population of approximately 560 million women above 15 years of age, who are at risk of developing cervical cancer. Current estimates indicate approximately 100,000 new cases of cervical cancer are diagnosed each year and 30,000 deaths occur annually due to cervical cancer in China. It is believed mortality due to cervical cancer has been increasing in China. In response, China has increased efforts to screen more women, especially in rural areas where the laboratory infrastructure for traditional screening tests is lagging. Because LuViva does not require a laboratory infrastructure and produces an immediate result at the point of care, it is well suited to screening women for cervical cancer in these environments.

On October 5, 2021 Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, reported an expansion of its expert-led Alliance Panel product offering (Press release, Twist Bioscience, OCT 5, 2021, View Source [SID1234590884]). Designed through collaboration with world-leading experts, Twist Alliance Panels combine validated content with Twist next-generation sequencing (NGS) workflow, target enrichment and DNA probes. In an extension of Twist’s OEM strategy, Twist will market products designed by key opinion leaders in a wide range of clinical applications and powered by Twist tools through the Alliance Panel program. In return, expert collaborators receive a royalty on the sale of products and will carry partner branding.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Data generated and validated by experts around the world bring incredible value to the research community," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "By working together, we are leveraging this extensive knowledge, providing the global community with better research tools, all powered by Twist products, and also ensuring the experts involved receive recognition and royalties for their hard work."

As the first Alliance Panel offering, Twist collaborated with the Regeneron Genetics Center LLC (RGC), a wholly-owned subsidiary of Regeneron, to develop the Twist Diversity SNP Panel, a custom NGS population genetics genotyping assay available to researchers globally for population genomics studies.

Today, Twist and AnchorDx launched the Twist Alliance Pan-cancer Methylation Panel based on The Cancer Genome Atlas (TCGA) database, including 31 cancer types and 47 TCGA database disease entities. The pan-cancer profile saves customers sequencing costs and reduces the complexity of analysis. Validation studies were conducted using tumor biopsy samples from breast cancer, colorectal cancer and non-small cell lung cancer. DNA methylation regions included in the panel have been found to clearly differentiate cancer tissues from the non-malignant tissue in these three cancer types, among the most common cancers.

About Twist Alliance Panels

In partnership with leading research institutions from around the world, Twist has curated a collection of high-quality target enrichment panels for applications ranging from carrier screening to cancer diagnostics and whole exome sequencing. The Twist Alliance Panels combine the strengths of precise, highly uniform oligonucleotide synthesis with the specialty expertise of leading scientific research partners.

Well designed, custom target enrichment panels enable increased sequencing depth on target genes while reducing overall sequencing. This allows for more sensitive detection of target sequences and higher confidence variant detection.